Cite
MLA Citation
A. Blauvelt et al.. “A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 24‐week efficacy and safety results from a randomized, double‐blinded trial.” British journal of dermatology, vol. 184, 2021, pp. 1047–1058. http://access.bl.uk/ark:/81055/vdc_100132239808.0x000055